Article image
Article image
Article image
Article image

The two doctors responsible for $400,000 Swedish-New Zealand research into a common form of blood deficiency are shown at Christchurch Hospital with some of the equipment used. Professor R. W. Carrell, left, the professor of clinical biochemistry at the Christchurch Clinical School, and Dr Jan-Olaf Jeppsson, of Mahno General Hospital in Sweden, are engaged in research on anti-trypsin deficiencies in the blood, which are major causes of lung and liver disease. Financial support for the joint venture, which started this month, comes from the Medical Research Councils in Sweden and New Zealand.

This article text was automatically generated and may include errors. View the full page to see article in its original form.
Permanent link to this item

https://paperspast.natlib.govt.nz/newspapers/CHP19801229.2.89

Bibliographic details

Press, 29 December 1980, Page 11

Word Count
92

The two doctors responsible for $400,000 Swedish-New Zealand research into a common form of blood deficiency are shown at Christchurch Hospital with some of the equipment used. Professor R. W. Carrell, left, the professor of clinical biochemistry at the Christchurch Clinical School, and Dr Jan-Olaf Jeppsson, of Mahno General Hospital in Sweden, are engaged in research on anti-trypsin deficiencies in the blood, which are major causes of lung and liver disease. Financial support for the joint venture, which started this month, comes from the Medical Research Councils in Sweden and New Zealand. Press, 29 December 1980, Page 11

The two doctors responsible for $400,000 Swedish-New Zealand research into a common form of blood deficiency are shown at Christchurch Hospital with some of the equipment used. Professor R. W. Carrell, left, the professor of clinical biochemistry at the Christchurch Clinical School, and Dr Jan-Olaf Jeppsson, of Mahno General Hospital in Sweden, are engaged in research on anti-trypsin deficiencies in the blood, which are major causes of lung and liver disease. Financial support for the joint venture, which started this month, comes from the Medical Research Councils in Sweden and New Zealand. Press, 29 December 1980, Page 11